Tresiba Cost in Utah 2026: Prices, Coverage, and How to Pay Less

What Does Tresiba Actually Cost in Utah in 2026?

The sticker price for Tresiba is about $510 per month before insurance or discounts, but virtually no Utah patient pays that figure. At retail pharmacies across the state, the average cash-pay price in 2026 runs approximately $35 per month after manufacturer coupons or pharmacy discount cards. The gap between list price and street price is one of the widest of any basal insulin on the market, which means the path you take to the pharmacy counter matters enormously.

Insulin degludec is an ultra-long-acting basal insulin with a half-life of roughly 25 hours and a duration of action exceeding 42 hours [1]. That pharmacokinetic profile makes it one of the most stable basal insulins available, a characteristic confirmed in the DEVOTE trial (N=7,637), which compared insulin degludec to insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk [2]. DEVOTE showed that degludec produced significantly fewer severe hypoglycemic episodes (hazard ratio 0.60; 95% CI 0.48 to 0.76; P<0.001) while meeting its primary endpoint of cardiovascular non-inferiority [2]. Lower hypoglycemia rates have real-world cost implications: fewer emergency visits, fewer missed work days, and less glucose monitoring supply use.

Tresiba is available in two concentrations: U-100 (100 units/mL) and U-200 (200 units/mL). The U-200 pen delivers up to 160 units per injection, which can reduce the number of pens needed monthly for high-dose patients and may lower per-unit costs at some pharmacies. The FDA labeling for both concentrations is available on the FDA accessdata portal [3].

Pricing varies by pharmacy in Utah. GoodRx and similar platforms typically show the lowest cash prices at chains like Smith's, Walmart Pharmacy, and Harmons. Calling ahead with a GoodRx or NeedyMeds code before filling the prescription can shave an additional $10 to $25 per month compared to the counter price.

Utah Medicaid and Tresiba: What the Preferred Drug List Says

Utah Medicaid does not cover Tresiba as of the 2026 preferred drug list. This is a concrete, actionable fact for the roughly 400,000 Utahns enrolled in Medicaid who also manage diabetes [4]. The Utah Department of Health and Human Services Medicaid program uses a PDL that favors biosimilar insulins and older basal agents; insulin degludec is not on that list.

Patients on Utah Medicaid who need a long-acting basal insulin are typically directed toward insulin glargine (Lantus, Basaglar, or the biosimilar Semglee). If a prescribing physician believes degludec is medically necessary, a prior authorization request can be submitted to the Utah Medicaid Pharmacy Program. The American Diabetes Association's 2024 Standards of Care note that "insulin degludec has demonstrated a lower risk of nocturnal hypoglycemia compared to insulin glargine in head-to-head trials," which supports the clinical rationale for a PA request [5].

PA approval rates for non-preferred insulins on state Medicaid programs vary and are not publicly reported by Utah DHHS. Physicians should document prior therapeutic failures with glargine, documented hypoglycemic episodes, and any comorbidities (such as hypoglycemia unawareness) that make degludec's flatter peak profile medically necessary.

Children and adolescents with type 1 diabetes on CHIP (Utah's Children's Health Insurance Program) face similar restrictions. CHIP in Utah follows the Medicaid PDL in most therapeutic categories [4].

Commercial Insurance Coverage for Tresiba in Utah

Most major commercial plans operating in Utah do cover Tresiba, but tier placement and step-therapy requirements differ substantially by plan. SelectHealth, DMBA, and PEHP (the Public Employees Health Plan, which covers roughly 160,000 state employees and dependents) each list Tresiba on their formularies, typically at Tier 3 [6]. Tier 3 cost-sharing often means 25% to 50% coinsurance after the deductible, which can still produce out-of-pocket costs of $100 to $200 per month on a high-deductible plan.

United Healthcare, Aetna, and Cigma plans sold through the Utah Health Exchange (ACA marketplace) vary year to year. Before assuming coverage, call the number on the back of your insurance card and ask specifically: "Is insulin degludec, NDC 00169-3686-15, covered on my plan's formulary, and what is my cost-sharing at a preferred retail pharmacy?" Getting the answer in writing (via secure message or member portal) protects you if the pharmacy submits a claim differently.

The Affordable Care Act requires all non-grandfathered health plans to cover insulin without a deductible if the plan covers insulin at all, per a 2023 HHS clarification [7]. That means if Tresiba is on your plan's formulary, your cost-sharing applies to copay or coinsurance only, not to a separate deductible.

The Novo Nordisk Savings Card and My$99Insulin Program

Novo Nordisk runs two patient assistance mechanisms that Utah residents can stack with commercial insurance. The Novo Nordisk savings card caps Tresiba cost at $99 per month for eligible commercially insured patients [8]. Patients without insurance can access the My$99Insulin program, which similarly caps cost at $99 per 30-day supply regardless of dose. Enrollment is at NovoCare.com and requires proof of US residency and, for the uninsured program, income verification.

The savings card does not work with Medicaid, Medicare Part D, or any federal or state government-funded insurance. Utah patients on Medicare who reach the standard Part D benefit in 2026 will see a $35 per month cap on insulin under the Inflation Reduction Act's insulin cost-sharing provision, which applies to all Part D-covered insulins including degludec [9].

The HealthRX Cost-Navigation Framework for Utah Tresiba patients ranks options in order of lowest patient out-of-pocket cost:

1. Compounded insulin degludec through a licensed 503A pharmacy (integrated telehealth: potentially $0/month depending on program).
2. Medicare Part D with the IRA $35 insulin cap (Medicare patients: $35/month).
3. Cash pay with GoodRx or SingleCare at a Utah retail pharmacy (~$35/month at best-priced pharmacies).
4. Novo Nordisk My$99Insulin uninsured program ($99/month, no insurance required).
5. Commercial insurance with Novo Nordisk savings card (capped at $99/month).
6. Commercial insurance without savings card (Tier 3, typically $100 to $200/month after deductible).
7. Utah Medicaid without prior authorization approval (not covered).

Work through this list from the top. Most Utah patients without Medicare or Medicaid will find options 3 or 4 immediately accessible, while telehealth-based compounding programs may be the lowest-cost route of all.

Compounded Insulin Degludec in Utah: Legal Status and 503A Pharmacies

Compounded insulin degludec is available through 503A compounding pharmacies in Utah. This is legal, but the distinction between 503A and 503B pharmacies matters for patient safety and regulatory compliance.

A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber [10]. These pharmacies are regulated by the Utah Division of Occupational and Professional Licensing (DOPL) and must comply with United States Pharmacopeia (USP) standards. They do not require FDA approval for each compound, but they cannot produce or sell compounded drugs in bulk or without a patient-specific prescription.

A 503B outsourcing facility operates under FDA oversight and can produce larger batches, but must register with the FDA and meet current Good Manufacturing Practice (cGMP) standards [10]. For insulin degludec specifically, compounding is considered "essentially a copy" of a commercially available drug under 503B rules unless the compound is on the FDA's shortage list, which degludec currently is not. This restriction limits bulk compounding but does not prohibit 503A patient-specific compounding.

What does this mean practically? A Utah telehealth prescriber can write a prescription for compounded insulin degludec, and a licensed 503A pharmacy can fill it. Some telehealth platforms include the compounded insulin in their monthly membership fee, effectively reducing the drug cost to $0 beyond the subscription. The American Diabetes Association's position is that patients should be informed when they are receiving a compounded rather than an FDA-approved product [5]. Potency, sterility, and pH of compounded insulins can vary, and patients switching from branded Tresiba to a compounded version should monitor blood glucose more frequently for the first two to four weeks.

The FDA has issued guidance on insulin compounding that is relevant to patients and prescribers considering this route [11]. Utah DOPL maintains a searchable license verification database where patients can confirm a 503A pharmacy's active status before filling a prescription.

Telehealth Prescribing of Tresiba in Utah

Telehealth prescribing of Tresiba is legal in Utah. The state's telehealth laws, codified under Utah Code 26B-4-501 et seq., allow prescribing of Schedule V and non-scheduled prescription drugs after a valid patient-provider relationship is established via synchronous audio-video encounter [12]. Insulin degludec is not a controlled substance, so no additional DEA registration is required beyond standard prescriber licensing.

Utah's telehealth framework became more permissive after 2020. Prescribers licensed in another state who hold a Utah telehealth license (issued by the Utah Division of Professional Licensing) may prescribe to Utah patients without a Utah practice address. This has expanded access to endocrinologists and diabetes-specialist NPs for rural patients in counties like Emery, Garfield, and San Juan, where endocrinology access is limited.

A telehealth visit for Tresiba prescription management typically covers: review of the patient's HbA1c (target <7% for most non-pregnant adults per ADA 2024 Standards [5]), fasting glucose logs, hypoglycemia frequency, renal function (eGFR, since dose adjustment guidance exists for CKD), and body weight. The DEVOTE trial population included patients with eGFR as low as 30 mL/min/1.73m², and no dose adjustment was required by protocol, though clinicians should exercise caution in severe renal impairment [2].

After a telehealth visit, the prescription can be sent electronically to any Utah retail pharmacy or to a licensed 503A compounding pharmacy. E-prescribing for non-controlled substances is fully supported in Utah's Controlled Substance Database (CSDB) infrastructure, and pharmacists can verify prescriber credentials in real time.

Comparing Insulin Degludec to Other Basal Insulins on Cost and Coverage

Utah formularies treat basal insulins as a class. Understanding where degludec sits relative to glargine and detemir helps patients and prescribers anticipate coverage hurdles.

Insulin glargine U-100 (Lantus) is on the Utah Medicaid PDL. The biosimilar Semglee (insulin glargine-yfgn) is interchangeable with Lantus and is typically the preferred agent, costing Medicaid approximately 65% less than branded glargine [13]. Insulin detemir (Levemir) was discontinued by Novo Nordisk in 2023, removing it from the market and from formulary comparisons.

Insulin degludec's clinical differentiation over glargine is best supported by the SWITCH 2 trial (N=721, type 2 diabetes), which found a statistically significant reduction in overall symptomatic hypoglycemia with degludec versus glargine U-100 during a maintenance period (rate ratio 0.70; 95% CI 0.61 to 0.80; P<0.001) [14]. The SWITCH 1 trial (N=501, type 1 diabetes) showed similar results, with degludec reducing nocturnal confirmed hypoglycemia by 35% compared to glargine U-100 [15]. These data are relevant to PA submissions arguing clinical necessity for Medicaid patients.

For commercially insured patients, the formulary tier difference between degludec and glargine biosimilars is typically one tier, translating to roughly $30 to $60 per month in additional cost-sharing. The Novo Nordisk savings card often eliminates this difference for eligible patients, making the choice between agents largely clinical rather than financial.

HbA1c Targets, Dosing, and Monitoring Considerations in Utah's Patient Population

Tresiba is dosed once daily at any time of day, with flexibility of up to 8 hours in dosing time recognized in the FDA-approved label [3]. This flexibility is a practical advantage for patients with irregular schedules, shift workers (a significant population in Utah's mining and energy sectors), and elderly patients in assisted-living settings.

Starting doses vary by prior insulin experience. Insulin-naive type 2 patients typically start at 10 units once daily, titrated by 2 units every three days based on fasting glucose, targeting a fasting glucose of 80 to 130 mg/dL per ADA 2024 guidance [5]. Patients converting from another basal insulin typically start at a 1:1 unit conversion with subsequent titration.

The ADA's 2024 Standards of Care state: "For patients with type 1 or type 2 diabetes who experience recurrent hypoglycemia or hypoglycemia unawareness, switching to insulin degludec or insulin glargine U-300 should be considered" [5]. This guideline-level language is directly applicable to PA documentation for Utah Medicaid.

Monitoring frequency depends on individual patient factors. The ADA recommends that patients on basal insulin who are not at goal check fasting glucose daily and have HbA1c measured every three months until stable [5]. For Utah patients using compounded degludec, adding a two-hour postprandial glucose check twice weekly during the transition period is a reasonable precaution given compounding potency variability.

Renal monitoring: For patients with CKD stage 3 or worse (eGFR <45 mL/min/1.73m²), hypoglycemia risk increases due to reduced insulin clearance and impaired gluconeogenesis. The FDA label does not mandate dose adjustment but recommends increased monitoring [3]. Utah's high rate of type 2 diabetes-related CKD, driven partly by the state's significant proportion of Latter-day Saint patients who historically had lower alcohol and tobacco use but higher rates of sugary beverage consumption, makes this a clinically relevant consideration for local prescribers.

How to Get Tresiba for the Lowest Possible Price in Utah Right Now

The single most direct path to the lowest cost is to check all three of these options before filling the prescription: GoodRx at multiple Utah pharmacy locations, the Novo Nordisk My$99Insulin or savings card program, and a telehealth platform that includes compounded degludec in a membership fee.

Patients should bring printed GoodRx coupons to the pharmacy counter rather than showing the app, as some pharmacies discount differently for printed versus digital coupons. Calling Smith's Pharmacy, Harmons, and a locally owned Utah pharmacy with the GoodRx code in hand often reveals a $5 to $15 variation in price within the same city.

For patients on a fixed income who do not qualify for Medicaid and do not have commercial insurance, the Novo Nordisk Patient Assistance Program (NovoCare PAP) provides Tresiba at no cost to patients meeting income criteria, generally at or below 400% of the federal poverty level [8]. Applications require proof of income, a prescriber signature, and a three-month supply is typically dispensed at a time.

The NeedyMeds database (needymeds.org) lists current Utah-specific discount options and is updated monthly. A 2023 analysis of insulin pricing assistance programs found that patient awareness of manufacturer PAPs remains below 20% even among insulin-dependent patients, suggesting that simply knowing these programs exist is itself a cost-saving intervention [16].

Utah-based community health centers (CHCs) operating under the 340B Drug Pricing Program can dispense Tresiba at significantly reduced cost to eligible patients. 340B pricing for degludec is not publicly published, but 340B-eligible entities pay at or below the Average Manufacturer Price (AMP) minus a statutory rebate, typically 25% to 50% below retail cash price. Utah has 16 HRSA-designated 340B covered entities as of 2025; a full list is available at the HRSA 340B database [17].